Atossa Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Atossa Therapeutics Inc.
- Former names
- Atossa Genetics Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ATOS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001488039
- EIN
- 26-4753208
Board of directors
-
Gregory L. Weaver · Director · Former EVP, CFO, & DirectorSince 2023
-
H. Lawrence Remmel · DirectorSince 2023
-
Jonathan Finn · DirectorSince 2023
-
Richard I. Steinhart · DirectorSince 2023
-
Shu-Chih Chen · DirectorSince 2023
-
Stephen J. Galli · DirectorSince 2023
-
Steven C. Quay · Director · President & CEOSince 2023
-
Tessa Cigler · DirectorSince 2024
Chief executives
Steven C. Quay
· President & CEO
Dates unknown
Director election results
Annual meeting of May 4, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
59.9%
-
83.5%
Board connections
1 of this board's directors also sit on 1 other board.
- via Richard I. Steinhart
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 12, 2026 | Richard I. Steinhart Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Shu-Chih Chen Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | H. Lawrence Remmel Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Jonathan Finn Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Stephen J. Galli Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Tessa Cigler Director | Grant or award | +10,000 | — | — |
| Mar 27, 2026 | Steven C. Quay Director, Officer (President & CEO) | Grant or award | +65,000 | — | — |
| Mar 26, 2026 | Daniel Mark James Officer (Chief Financial Officer) | Grant or award | +63,000 | — | — |
| Jan 20, 2026 | Steven C. Quay Director, Officer (President & CEO) | Grant or award | +325,203 | — | — |
| May 21, 2025 | Steven C. Quay Director, Officer (President & CEO) | Open-market purchase | +11,239 | $0.88 | $9,890 |
| Mar 26, 2025 | H. Lawrence Remmel Director | Open-market purchase | +10,000 | $0.70 | $7,000 |
| Apr 10, 2024 | Jonathan Finn Director | Open-market purchase | +25,000 | $1.77 | $44,250 |
| Nov 15, 2023 | Gregory L. Weaver Director, Officer (Former EVP, CFO, & Director) | Open-market sale | −50,000 | $0.65 | $32,500 |
| Jun 20, 2023 | Gregory L. Weaver Director, Officer (EVP & CFO) | Open-market purchase | +50,000 | $0.97 | $48,500 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.